CONFERENCE UPDATE: ILC 2022

Micro-elimination HCV through an industry, prison healthcare and patient organization partnership

GASTROENTEROLOGY & HEPATOLOGY
08 Nov 2022

Glossary: COVID-19: Coronavirus disease of 2019; DAA: Direct-acting antiviral; HCV: Hepatitis C virus; HITT: The High Intensity Teest and Treat program; PPG: Practice plus group; RNA: Ribonucleic acid

Get access to our exclusive articles.
Related Articles

Evaluation of the clinical and economic values of SOF/VEL in CHC patients
GASTROENTEROLOGY & HEPATOLOGY
08 Nov 2022

Changing HCV patient profiles from large multinational real-world SOF/VEL dataset

Glossary: DAA: Direct-acting antiviral; GT3: Genotype 3; HCV: Hepatitis C virus; IV: Intravenous; LFU: Lost to follow-up; NS5A: Nonstructural protein 5A; RBV: Ribavirin; RNA: Ribonucleic acid; SOF/VEL: Sofobuvir/velpatasvir; SVR: Sustained virologic response

GASTROENTEROLOGY & HEPATOLOGY
08 Nov 2022

Health economic outcome of A5360 MINMON

Glossary: DAA: Direct-acting antiviral; HCV: Hepatitis C virus; RNA: Ribonucleic acid; SoC: Standard of care; SOL/VEL: Sofosbuvir/velpatasvir; SVR: Sustained virologic response; the US: The United States
GASTROENTEROLOGY & HEPATOLOGY
08 Nov 2022

HCC incidence after HCV cure among patients with advanced fibrosis of cirrhosis

Glossary: aRR: Adjusted rate ratio; CI: Confidence interval; HCC: Hematocellular carcinoma; HCV: Hepatitis C virus

GASTROENTEROLOGY & HEPATOLOGY ONCOLOGY
08 Nov 2022

Predictive factors for LFU pre- and post-HCV treatment

Glossary: BC: Breast cancer; HCV: Hepatitis C virus; IDU: Injection drug user; LFU: Lost to follow-up; OR: Odds ratio; RNA: Ribonucleic acid; SVR: Sustained virologic response

GASTROENTEROLOGY & HEPATOLOGY ONCOLOGY ...
08 Nov 2022

Comedication in patients with HCV, addiction or drug abuse treated with DAA

Glossary: DAA: Direct-acting antiviral; DDI: Drug-drug interaction; GLE/PIB: Glecaprevir/Pibrentasvir; HCV: Hepatitis C virus; PWID: People who inject drug; SOF/VEL: Sofosbuvir/velpatasvir

GASTROENTEROLOGY & HEPATOLOGY
08 Nov 2022

Screening and cooperation model of HCV elimination in ouy-patients and PWIDs

Glossary: Ab: Antibody; GOP: General out-patient; HCC: Hematocellular carcinoma; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; PWID: People who inject drug; RNA: Ribonucleic acid; SOF/VEL: Sofosbuvir/velpatasvir
GASTROENTEROLOGY & HEPATOLOGY
08 Nov 2022

The disease burden of hepatitis B and hepatitis C

Viral hepatitis is one of the leading causes of death worldwide. In fact, 90% of this burden is attributed to the sequelae of infections of HBV and HCV.1 In view of this, the WHO established a goal in 2015 to eliminate HBV and HCV infections by the year of 2030.1 With commitment to both prevention and treatment by increasing the reach of vaccination programs and launching screening and treatment initiatives, elimination is a feasible goal.1
GASTROENTEROLOGY & HEPATOLOGY
08 Nov 2022

SOF/VEL demonstrates high effectiveness against HCV in prison setting

In a retrospective, integrated analysis, the treatment regimen of sofosbuvir/velpatasvir (SOF/VEL) once daily for 12 weeks was found to be effective in eliciting a sustained virological response (SVR) in the prison population with hepatitis C virus (HCV) infection.1 The study presented supportive evidence of using this simple regime across a broad range of HCV patients and across various settings with minimal monitoring requirements.1
08 Nov 2022

HITT as part of the HCV elimination program in the United Kingdom
GASTROENTEROLOGY & HEPATOLOGY
07 Nov 2022